ArticleInternational journal of endocrinology2019

Liraglutide Attenuates Nonalcoholic Fatty Liver Disease through Adjusting Lipid Metabolism via SHP1/AMPK Signaling Pathway.

Peng Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.